Facebook Twitter Linkedin Google Plus

Five-year Results of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin lymphoma

Five-year Results of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin lymphoma +

The final data of the brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda Oncology) monotherapy pivotal phase II clinical trial in relapsed or refractory (R/R) classical Hodgkin lymphoma were published in the July 18, 2016 edition of Blood, a peer reviewed journal published by the American Society of Hematology. The article, which summarizes the five-year, end-of-study results, highlights data showing that patients who attained a complete response achieved long-term disease control.

Read more

Delivering Cures Through Science: AACR Presents Research Updates

Delivering Cures Through Science: AACR Presents Research Updates +

The Interaction and collaboration between scientist promotes and stimulates discovery leading to medical breakthroughs. This year the annual meeting of the American Association for Cancer Research in New Orleans (April 16 - 20) is expected to draw more than 19,000 scientists, clinicians, advocates, and others to discuss advances in the field of cancer science. The multidisciplinary program is expected to include nearly 100 papers and posters covering all aspects of antibody-drug conjugates - from early discovery to preclinical and clinical trials.

Read more

ASCO 2016: Revolutionizing Cancer Treatment and Care

ASCO 2016: Revolutionizing Cancer Treatment and Care +

It’s just a few more weeks until the start of the 2016 annual meeting of American Society of Clinical Oncology (ASCO). This year, the theme of the meeting is "Collective Wisdom: The Future of Patient-Centered Care and Research", emphasizing that the combined knowledge from various disciplines, cancer types, treatment approaches, and big data technologies is essential to progress. Among the more than 5,200 abstracts to be presented are a large number offering a better understanding of cancer biology and chemistry, focusing on targeted therapies and personalized/precision medicine including antibody-drug conjugates, PD-1's and BiTe's, to name a few. Read our overview and find out what to expect during the 2016 annual meeting.

Read more

ABT-414 Shows Encouraging Phase I Trial Results in EGFR Amplified, Recurrent Glioblastoma

ABT-414 Shows Encouraging Phase I Trial Results in EGFR Amplified, Recurrent Glioblastoma +

Initial results from an open label, Phase I study of ABT-414, an investigational antibody drug conjugate or ADC for the treatment of patients with epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM), shows no dose-limiting toxicities and frequent, reversible ocular toxicities. These results, were presented at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill.

Read more

News


View all

Editorial


View all


Latest Articles


View all

Expert Interview


View all

Must Read Articles


View all

How to Contribute

Featured Events


View all events


Newsletter sign up

To subscribe to our weekly newsletter please send us your email address...


Lonza

Go to top

ADC Review
is made possible by:

Stay in touch

Facebook Twitter Linkedin Google Plus

Skip to toolbar